Stockpolly
Search
SRZN · NASDAQ · Biotechnology

Surrozen (SRZN)

Develops multifunctional Wnt-mimetic biologics for serious retinal vascular and inflammatory eye diseases.

$23.79
Pre-market+1.22 (+5.41%)
At close$22.57(+1.67%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000101111155
Cost of revenue000000000000
Gross profit0000101111155
11109999111012131515
Research & development665555768998
444444444467
General & administrative444444444467
Other expenses200000000000
Operating income−11−10−9−91−9−10−9−11−13−10−10
110−16−3−19−1749−61−171−11761
Interest income110000011111
Other non-operating income−2001631917−4961171117−61
Income before tax−10−9−9−25−1−28−2740−72−183−12850
Net income from continuing operations−10−9−9−25−1−28−2740−72−183−12850
Net income−10−9−9−25−1−28−2740−72−183−12850
EPS, basic−$5.14−$4.32−$4.24−$7.99−$0.44−$8.60−$7.43$2.55−$8.36−$23.87−$11.65$2.75
EPS, diluted−$5.14−$4.32−$4.24−$7.99−$0.44−$8.60−$7.43$2.55−$8.36−$23.87−$11.65−$0.41
Weighted average shares, basic22233349991112
Weighted average shares, diluted22233349991123
EBITDA−9−9−8−25−1−28−2740−72−183−12750
Depreciation & amortization000000000000
EBIT−10−10−9−25−1−28−2740−72−183−12850